Thymalfasin

胸腺法新

Report date: 2026/03/23 20:03:44
NME

Base Information

Drug NameThymalfasin
Drug Alias Name胸腺肽α1Timalfasina胸腺素α1ThymalfasinumThymalfasine +[10] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionThymosin alpha-1 agonists
TargetsThymosin alpha-1
Therapy Area/IndicationsKidney Failure, ChronicColorectal NeoplasmsCarcinoma, Hepatocellular +[7] 
Global Approved IndicationsHepatitis B, Chronic
Approved Indications in ChinaHepatitis B, Chronic
Original Approved Country/TerritoryMainland China
Original Approved DateN/A
Country/TerritoryUnited StatesItalyMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesFudan UniversityChengdu Diao Jiuhong Pharmaceutical FactorySichuan Yuanji Pharmaceutical Co Ltd
Inactive CompaniesSciclone PharmaceuticalsSigma-Tau Ifr SpaSun Yat-Sen University
Active IndicationsColorectal NeoplasmsHepatitis CHepatitis B, Chronic +[4] 
Inactive IndicationsKidney Failure, ChronicCarcinoma, HepatocellularSepsis

Other Information

ATC CodeA05A
Related LinksDrugBankKEGG